Shares of JBS (JBSS32) fell 7.82% by 1:47 p.m. on Thursday (Dec 11, 2026), dropping from R$ 69.01 to R$ 63.61 while the Ibovespa rose 0.17%. The move exceeds the unusual variation threshold for the stock (6.61%) and stems from a clear trigger: a report published by BTG Pactual the previous day. While BTG maintained its Buy rating on JBSS32, it cut its 2027 earnings estimates and cautioned that the R$ 2.97 billion acquisition of Flora—coming alongside weak Q3 2026 earnings—raises questions about JBS's capital allocation strategy. Trading was still ongoing at the time of calculation, and the final price change may differ.
Why Did JBSS32 Fall Today?
No new regulatory filings were submitted to the CVM over the past 48 hours. The selling pressure stems from a BTG Pactual report released on Tuesday (11/11). The bank maintained its Buy rating for JBSS32 with a R$ 100 price target, but lowered its 2027 net income projection by 12%—from US$ 1.22 billion to US$ 1.07 billion—and trimmed its EBITDA forecast for the same year by 3%, from US$ 5.93 billion to US$ 5.75 billion. The central argument from BTG's analysts is that narrowing JBS's valuation discount relative to global peers will depend not only on operational execution, but also on how management handles capital allocation going forward.
In practical terms, BTG is signaling that the margin recovery thesis supporting its R$ 100 price target could take longer to play out if JBS continues pursuing acquisitions before operational results normalize. The investment thesis is not broken—its timeline has simply been extended. For investors who bought the stock expecting a valuation rerating in 2026 or early 2027, this shifts the timeline.
What BTG Revised and Why Flora Is Center Stage
BTG's report is the first major sell-side research to quantify the combined impact of three sequential events: Q3 2026 earnings, the Flora purchase, and the Canal Rural acquisition. The Q3 2026 results, reported on Nov. 10, showed net income of US$ 164 million—down 71% year-over-year—with adjusted EBITDA falling 26.8% to US$ 3.74 billion, weighed down by U.S. cattle costs and compressed U.S. pork margins.
Regarding Flora, BTG noted that the acquisition multiple of 7x EBITDA drops to 4.9x when factoring in synergies estimated by JBS itself. Flora generated net revenue of R$ 2.9 billion in the 12 months ended September 2026, operates five plants, and owns brands such as Minuano, Francis, Neutrox, and OX. Canal Rural was acquired for US$ 11 million. Both transactions are expected to close in December 2026.
The main issue raised by BTG is not the multiple itself, but the context: JBS paid for Flora using treasury shares near 52-week lows. That means for every dollar of equity value delivered in the deal, the company surrendered more shares than it would have at its March valuation levels. While the resulting 2027 earnings per share dilution is under 1%—negligible on its own—the opportunity cost of using depressed stock as currency was interpreted by the market as suboptimal capital allocation. The bank also highlighted that free cash flow turned negative in Q3 2026, amplifying concerns about pursuing M&A while cash flow is constrained.
A New Share Issuance? Clearing Up the Confusion
The most frequent question regarding JBSS32 in recent days centers on a potential "new share issuance." There is no new issuance: JBS paid for Flora using treasury shares rather than issuing new stock on the market, as detailed in our analysis of the transaction structure published on Nov. 9. The confusion is understandable: treasury shares are stock the company previously repurchased and held; using them as acquisition currency delivers equity without a formal follow-on offering. For existing shareholders, the dilutive effect is real—under 1% on 2027 EPS according to BTG—but it exists. What the market is pricing in today is not an issuance per se, but the broader combination: using cheap stock + weak quarterly earnings + entering two non-core sectors before core operations have recovered.
How Industry Peers Performed in the Same Session
The Ibovespa was trading higher at the time, and the median absolute price move among stocks tracked by the site was 1.54%, making JBS's drop a clear outlier. SOJA3 (Boa Safra Sementes) also fell significantly, down 5.58%, but that move had company-specific drivers detailed in our SOJA3 coverage. Among meatpackers, BEEF3 (Minerva) gained 3.32% in the same session—moving in the opposite direction, which isolates the pressure on JBSS32 and rules out a sector-wide sell-off.
The fact that Minerva (BEEF3) gained while JBS fell in the same session confirms that the pressure is stock-specific rather than a systemic issue across the protein sector. JBS trading volume reached R$ 112.1 million by 1:47 p.m.—above its historical average for that time of day, pointing to institutional repositioning rather than minor retail noise.
What Was Verified
Regulatory filings submitted to the CVM in the past 48 hours: none. We reviewed 14 news headlines published over the last 24 hours across Google News and our site archives; two directly addressed the price movement—BTG's report and the M&A context. We monitored the Ibovespa and the sector peers listed above. A Money Times headline on Nov. 11 ("JBS remains cheap, but acquisitions raise questions and could delay rerating, says BTG") attributes the diagnosis directly to BTG—it reflects the bank's research report, not an editorial opinion of this site. No new disclosures were released by JBS itself on Thursday.
The company's immediate fundamentals did not change today: the Flora transaction was already announced, Q3 2026 earnings were public as of Monday, and BTG kept its Buy rating. What today reflects is the market pricing in execution risk—the possibility that margin recovery will take longer than expected as management allocates capital to M&A outside its core protein operations. For shareholders, the key variable to monitor is not today's stock price, but whether JBS can deliver concrete signs of margin normalization in upcoming quarters. The timeline starts with the closing of the acquisitions in December and continues with Q4 2026 results.
Closing of acquisitions in December 2026 — JBS expects to finalize the Flora and Canal Rural transactions by December. Investors will watch for formal details on expected synergies: the projected drop in Flora's valuation multiple from 7x to 4.9x EBITDA is currently management's internal estimate, and confirming that target will be the deal's first credibility test.
U.S. beef margins in Q4 2026 — BTG maintained a conservative 0.5% EBITDA margin forecast for JBS's U.S. beef business in 2027. Results above that level would serve as a major catalyst for a valuation rerating, while underperformance would confirm that recovery will take longer.
Further M&A announcements — BTG flagged the pace of acquisitions as the single largest risk to the stock's timing. Any additional deal, particularly outside core animal proteins, would likely increase selling pressure while core earnings remain depressed.
JBS shares (JBSS32) dropped 7.82% on Dec 11, 2026 (as of 1:47 p.m.; trading remained open and the final change may differ). The primary catalyst was a BTG Pactual report published on 11/11: while maintaining a Buy rating and a R$ 100 price target, the bank cut its 2027 earnings forecast by 12% and warned that aggressive M&A—specifically acquiring Flora for R$ 2.97 billion and Canal Rural for US$ 11 million using treasury shares near 52-week lows during a quarter when net income sank 71% and free cash flow turned negative—could delay a stock rerating. The Ibovespa rose over the same period, and BEEF3 gained 3.32%, confirming the selling pressure was company-specific.
